title: Evaluation of regional cerebral glucose metabolism in patients with malignant lymphoma of the body using statistical image analysis.
abstract: OBJECTIVE
  The aim of this study was to clarify the characteristics of regional cerebral glucose metabolic abnormalities in patients with malignant lymphoma of the body using statistical image analyses. Post-therapeutic changes in cerebral glucose metabolism were also evaluated.
  
  
  METHODS
  The subjects consisted of 30 patients, including 16 patients with diffuse large B-cell lymphoma and 14 patients with other types of lymphoma. Patients with primary cerebral lymphoma were excluded from this study. All patients underwent CT and whole-body FDG-PET scans, including 4-min brain scans using a dedicated PET/CT scanner during both the pre- and post-treatment periods. The whole-body scans started 60 min after the administration of 185 MBq of FDG, after which the brain data were extracted from whole-body data. The degree of regional cerebral glucose metabolism was evaluated on a voxel-by-voxel basis using statistical parametric mapping (SPM). The total tumor glycolytic volume of the body was measured using a separate workstation. The normal control subjects were 12 persons who underwent medical check with FDG-PET/CT and had no lesions suggesting malignant tumor.
  
  
  RESULTS
  The level of regional cerebral glucose metabolism decreased in association with an increase in the total glycolytic volume in the bilateral frontal and parietal cortices. After chemotherapy, the statistical image analysis demonstrated an interval recovery of the cerebral glucose metabolism of the bilateral parietal and occipital cortices in the good responders, whereas there were no significant differences observed in regional cerebral glucose metabolism between the pre- and post-treatment images in the poor responders. Comparison between normal control subjects and patients with pre-treatment lymphoma also showed that the regional cerebral glucose metabolism decreased in the parieto-occipital cortices in patients with lymphoma compared to normal control subjects.
  
  
  CONCLUSIONS
  We demonstrated that patients with malignant lymphoma of the body exhibited abnormal regional cerebral glucose metabolism, which improves after chemotherapy. Although the mechanism underlying the reduction of cerebral glucose metabolism remains unclear, our findings indicate the functional alternation and/or subclinical damage of the brain in patients with malignant lymphoma.
authors.affiliation: Department of Radiology, Fukuoka University Hospital, Fukuoka, Japan, nono@fukuoka-u.ac.jp.
authors.forename: Masanari
authors.initials: M
authors.lastname: Nonokuma
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Kuwabara
authors.forename: Koichi
authors.initials: K
authors.lastname: Takano
authors.forename: Kazuo
authors.initials: K
authors.lastname: Tamura
authors.forename: Kenji
authors.initials: K
authors.lastname: Ishitsuka
authors.forename: Kengo
authors.initials: K
authors.lastname: Yoshimitsu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002540:Cerebral Cortex / Q000000981:diagnostic imaging / Q000378:metabolism*; D005260:Female; D019788:Fluorodeoxyglucose F18; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D007091:Image Processing, Computer-Assisted / Q000379:methods; D008223:Lymphoma / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000378:metabolism*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D051598:Whole Body Imaging
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D005947:Glucose
references.citation: J Clin Oncol. 1989 Nov;7(11):1630-6
references.pmid: 2809679
references.citation: JAMA. 1983 Feb 11;249(6):751-7
references.pmid: 6823028
references.citation: Acta Oncol. 1992;31(6):641-3
references.pmid: 1466892
references.citation: Lancet Neurol. 2002 Sep;1(5):294-305
references.pmid: 12849427
references.citation: J Comput Assist Tomogr. 1988 Jan-Feb;12(1):47-8
references.pmid: 3257221
references.citation: N Engl J Med. 1998 May 7;338(19):1378-80
references.pmid: 9571261
references.citation: Mayo Clin Proc. 2010 Sep;85(9):838-54
references.pmid: 20810794
references.citation: Br J Haematol. 2004 Oct;127(2):173-83
references.pmid: 15461623
references.citation: Eur J Nucl Med Mol Imaging. 2004 Mar;31(3):325-9
references.pmid: 14647988
references.citation: Hematol Oncol. 2009 Jun;27(2):61-70
references.pmid: 19247977
references.citation: Ann Nucl Med. 2010 Dec;24(10):707-11
references.pmid: 20824395
references.citation: Ann Neurol. 1984 Dec;16(6):649-54
references.pmid: 6335378
references.citation: Am J Psychiatry. 1974 Dec;131(12):1323-7
references.pmid: 4432930
references.citation: J Clin Oncol. 2007 Feb 10;25(5):579-86
references.pmid: 17242396
references.citation: Psychooncology. 1999 Jul-Aug;8(4):283-6
references.pmid: 10474846
references.citation: Neurology. 1991 Feb;41(2 ( Pt 1)):228-33
references.pmid: 1992366
references.citation: Cancer. 1996 Sep 1;78(5):1131-7
references.pmid: 8780554